Who are Voltron Therapeutics, Inc.'s investors?

Voltron Therapeutics, Inc.'s investors include Lucius Partners.

How much funding has Voltron Therapeutics, Inc. raised?

Voltron Therapeutics, Inc. has disclosed $9.4M raised across 4 rounds.

Where is Voltron Therapeutics, Inc. headquartered?

Voltron Therapeutics, Inc. is headquartered in New York, US.

Voltron Therapeutics, Inc.

New York, US · Founded 2017 · Delaware corporation · 1 known investors

Biotech

Founders & leadership

Matthew DuffyPresident

Patrick GallagherChief Executive Officer

Matthew EitnerNamed on SEC filing

Anthony ZookNamed on SEC filing

Paul KornerNamed on SEC filing

James AhernNamed on SEC filing

Investors · 1

Lucius PartnersreportedNew York

Reported raises · per SEC filings

Form D private placements

$9.4M disclosed across 4 rounds · 2019–2022

▶$3.2MraisedNov 2023 · 63 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Matthew EitnerDirector
Paul KornerDirector
James AhernDirector
Anthony ZookDirector
Matthew DuffyExecutive Officer, Director
Patrick GallagherExecutive Officer, Director

Amount sold: $3.2M
Sales commissions: $385.3K
Placement agents: Laidlaw & Company (UK) Ltd.
First sale: Oct 2022
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$300KraisedJun 2022 · 1 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

James AhernDirector
Matthew EitnerDirector
Matthew DuffyExecutive Officer, Director
Patrick GallagherExecutive Officer, Director
Anthony ZookDirector
Paul KornerDirector

Offering amount: $5M
Amount sold: $300K
Sales commissions: $36K
Placement agents: Laidlaw & Company (UK) Ltd.
First sale: Jun 2022
Incorporated: Corporation, Delaware, 2017
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$2.5MraisedSep 2021 · 36 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

James AhernDirector
Paul KornerDirector
Matthew DuffyExecutive Officer, Director
Matthew EitnerDirector
Anthony ZookDirector
Patrick GallagherExecutive Officer, Director

Offering amount: $12M
Amount sold: $2.5M
Sales commissions: $250.2K
Placement agents: Laidlaw & Company (UK) Ltd.
First sale: Aug 2021
Incorporated: Corporation, Delaware, 2017
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$3.3MraisedJul 2021 · 49 investors · Pharmaceuticals

Rule 506(b)

Officers, directors & promoters on the filing

Matthew DuffyExecutive Officer, Director
Matthew EitnerDirector
Anthony ZookDirector
Paul KornerDirector
James AhernDirector
Patrick GallagherExecutive Officer, Director

Offering amount: $3.3M
Amount sold: $3.3M
Sales commissions: $402K
Proceeds to insiders: $283.5K
Placement agents: Laidlaw & Company (UK) Ltd.
First sale: Oct 2019
Incorporated: Corporation, Delaware, 2017
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Voltron Therapeutics, Inc. Enters into Sponsored Research Agreement with The Vaccine & Immunotherapy Center at the Massachusetts General Hospital to Advance the Development of a Personalized Cancer Vaccine - BioSpacebiospace.com · Jun 2020

Frequently asked questions

Who are Voltron Therapeutics, Inc.'s investors?: Voltron Therapeutics, Inc.'s investors include Lucius Partners.
How much funding has Voltron Therapeutics, Inc. raised?: Voltron Therapeutics, Inc. has disclosed $9.4M raised across 4 rounds.
Where is Voltron Therapeutics, Inc. headquartered?: Voltron Therapeutics, Inc. is headquartered in New York, US.